Insulet Yönetim
Yönetim kriter kontrolleri 2/4
Insulet CEO'su Ashley McEvoy, Apr2025 tarihinde atandı, in görev süresi 1.08 yıldır. in toplam yıllık tazminatı $ 19.10M olup, şirket hissesi ve opsiyonları dahil olmak üzere 3.8% maaş ve 96.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.009% ine doğrudan sahiptir ve bu hisseler $ 963.14K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.1 yıl ve 3.3 yıldır.
Anahtar bilgiler
Ashley McEvoy
İcra Kurulu Başkanı
US$19.1m
Toplam tazminat
| CEO maaş yüzdesi | 3.82% |
| CEO görev süresi | 1.1yrs |
| CEO sahipliği | 0.009% |
| Yönetim ortalama görev süresi | 1.1yrs |
| Yönetim Kurulu ortalama görev süresi | 3.3yrs |
Son yönetim güncellemeleri
Recent updates
Seeking Alpha • May 13
Insulet: An Opportune Time To Get Involved
Summary Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Insulet raised full-year guidance to 21-23% sales growth and expects adjusted earnings to exceed $6.25 per share, reflecting strong Omnipod 5 adoption. Valuation has rebounded, with shares trading at 70x forward earnings and 10x sales, leaving little room for error amid decelerating growth. GLP-1 therapies and a voluntary recall pose risks, but international expansion and Omnipod 6 development support the long-term growth narrative. Read the full article on Seeking AlphaAnaliz Makalesi • May 13
Some May Be Optimistic About Insulet's (NASDAQ:PODD) Earnings
The most recent earnings report from Insulet Corporation ( NASDAQ:PODD ) was disappointing for shareholders. While the...
Anlatı Güncellemesi • Apr 26
PODD: Type 2 Automation And New Geographies Will Offset Device Concerns
The analyst price target for Insulet has been reduced by about $14, reflecting slightly lower fair value assumptions and modestly adjusted expectations for revenue growth, profit margins, and future P/E as analysts incorporate recent device correction headlines and intensifying patch pump competition into their models. Analyst Commentary Recent research on Insulet shows a mix of optimism and caution as analysts recalibrate their models after the Omnipod 5 device correction and ongoing competition in insulin patch pumps.
Yeni Anlatı • Apr 22
Execution Risks In Diabetes Automation Will Test Long Runway For Future Margin Expansion
Catalysts About Insulet Insulet develops and sells the Omnipod automated insulin delivery system for people living with diabetes. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Apr 11
PODD: Type 2 Automation And New Markets Will Offset Patch Pump Competition
Insulet's analyst price target has been trimmed by about $10 to roughly $340 as analysts factor in slightly higher discount rates, fine tune growth and margin assumptions, and react to recent competitive commentary and device related headlines, while largely maintaining constructive views on the Omnipod franchise. Analyst Commentary Recent research shows a clear split between optimistic and cautious views on Insulet, with many firms trimming price targets while still seeing meaningful potential in the Omnipod franchise.
Yeni Anlatı • Apr 08
Long-Term Diabetes Automation Adoption And Manufacturing Scale Will Drive Strong Future Potential
Catalysts About Insulet Insulet provides tubeless automated insulin delivery systems through its Omnipod platform for people living with diabetes worldwide. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 28
PODD: Type 2 Automation And New Markets Will Outweigh Patch Pump Competition
Analysts have trimmed Insulet's price target by about $3 to $351.43, balancing concerns about intensifying patch pump competition and the recent Omnipod 5 device correction with ongoing expectations for solid revenue growth and a premium future P/E of roughly 43x. Analyst Commentary Recent research paints a mixed picture for Insulet, with many firms trimming price targets yet largely maintaining positive ratings, while a smaller group has shifted to a more cautious stance.Anlatı Güncellemesi • Mar 13
PODD: Type 2 Adoption And Buybacks Will Offset Patch Pump Competition
Insulet's analyst price target has edged slightly lower to reflect modest tweaks to fair value, discount rate and profitability assumptions as analysts weigh recent device correction headlines and rising patch pump competition against ongoing Omnipod 5 adoption and broader sector health. Analyst Commentary Recent research updates on Insulet cluster around a common theme, with most firms trimming price targets while keeping generally positive views on execution, particularly around Omnipod 5 and Type 2 diabetes adoption, and a smaller group highlighting growing competitive and sentiment risks.Anlatı Güncellemesi • Feb 26
PODD: Type 2 Adoption And Buyback Program Will Support Future Leadership
Analysts have trimmed their price target on Insulet by about $15 to reflect slightly lower revenue growth assumptions, a modestly higher discount rate, and a reduced future P/E multiple, while still highlighting solid Omnipod 5 momentum and noting concerns about rising competition in insulin pumps and pricing. Analyst Commentary Street research on Insulet has shifted toward lower price targets, but most firms still keep positive or neutral ratings.Anlatı Güncellemesi • Feb 08
PODD: Type 2 Diabetes Ramp Will Support Multi Year Market Leadership
Narrative Update: Insulet Insulet's analyst price target edges lower by about $4 to reflect analysts' updated assumptions for slightly softer long term revenue growth and P/E multiple, partly offset by marginally higher profit margin expectations. Analyst Commentary Recent research on Insulet shows a split view, with some analysts trimming targets and ratings on competitive and valuation concerns, while others still see support from the company’s long term growth ambitions shared at its Investor Day.Anlatı Güncellemesi • Jan 23
PODD: Type 2 Diabetes Expansion Will Sustain Multi Year Market Leadership
The updated analyst price target on Insulet edges down slightly to about $374 from $378, as analysts factor in mixed Street commentary, with several firms trimming or raising targets in response to intensifying competition, ongoing Investor Day takeaways, and differing views on how the company's growth ambitions balance against valuation pressures. Analyst Commentary Street views on Insulet are split, with recent research highlighting both confidence in the company’s long term growth ambitions and concern about rising competition and valuation pressure.Anlatı Güncellemesi • Jan 09
PODD: Type 2 Diabetes Ramp Will Sustain Multi Year Market Leadership
Our analyst price target for Insulet edges slightly lower to $377.72. This reflects modest adjustments to discount rate, revenue growth, profit margin and future P/E assumptions in light of a wide range of updated Street targets between about $301 and $428, with analysts pointing to recent price target trims alongside ongoing optimism around Omnipod adoption and the type 2 diabetes opportunity.Anlatı Güncellemesi • Dec 22
PODD: Type 2 Diabetes Adoption Will Sustain Multi Year Market Leadership
Our Insulet fair value estimate is essentially unchanged, inching down by about $0.49 per share to $377.72. Analysts are raising price targets into the $380 to $428 range, citing confidence that the company can sustain above-market revenue growth driven by Omnipod 5 momentum and an expanding opportunity in Type 2 diabetes.Anlatı Güncellemesi • Dec 08
PODD: Type 2 Diabetes Expansion Will Drive Multi Year Market Leadership
Analysts have nudged their price targets on Insulet modestly higher, with recent upward revisions into the low to mid $400s per share reflecting confidence in the company’s multi year revenue growth outlook, expanding profitability, and strengthening position in both Type 1 and underpenetrated Type 2 diabetes markets following a series of beat and raise quarters and a bullish Investor Day. Analyst Commentary Street research following Insulet's recent Investor Day and quarterly updates has been overwhelmingly constructive, with a series of price target increases into the $350 to $428 range and multiple reaffirmed positive ratings.Anlatı Güncellemesi • Nov 24
PODD: Expansion Into Type 2 Diabetes Will Drive Market Leadership Ahead
Insulet's analyst fair value estimate has increased by approximately $12 to $378, as analysts cite robust multi-year growth forecasts and successful expansion in both Type 1 and Type 2 diabetes markets following recent company presentations and results. Analyst Commentary Recent research coverage of Insulet reflects ongoing optimism about the company's market positioning and future growth, as well as areas of continued scrutiny from analysts.Analiz Makalesi • Nov 09
Insulet Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Insulet Corporation ( NASDAQ:PODD ) just released its latest quarterly results and things are looking bullish. Results...Anlatı Güncellemesi • Nov 07
PODD: Expanding International Reach Will Drive Greater Diabetes Market Penetration
Analysts have raised their price target for Insulet by nearly $6 to $365.96. This reflects stronger revenue growth, improved margins, and continued business momentum highlighted in recent earnings updates and sector research.Anlatı Güncellemesi • Sep 19
Digital Diabetes Care Will Expand International Market Opportunities
Analysts have modestly raised Insulet’s price target, citing strong Q2 earnings, accelerated international Omnipod 5 adoption, and favorable reimbursement trends outweighing regulatory risks, resulting in a consensus target increase from $355.17 to $360.17. Analyst Commentary Bullish analysts cited Insulet's beat on Q2 earnings estimates, which prompted broad guidance raises and higher outlooks for FY25, reflecting renewed momentum in core business metrics.Analiz Makalesi • Sep 06
Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher
Insulet Corporation ( NASDAQ:PODD ) shareholders would be excited to see that the share price has had a great month...Anlatı Güncellemesi • Sep 04
Digital Diabetes Care Will Expand International Market Opportunities
Analysts remain bullish on Insulet due to accelerating revenue growth, increased guidance, and strong international momentum—particularly from Omnipod and favorable reimbursement trends—offsetting sector regulatory concerns, resulting in an unchanged consensus price target of $353.39. Analyst Commentary Bullish analysts cite Insulet's Q2 results showing reaccelerated growth, with revenue and earnings surpassing estimates and driving market share gains, especially among MDI conversions.Analiz Makalesi • Aug 14
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings
NasdaqGS:PODD 1 Year Share Price vs Fair Value Explore Insulet's Fair Values from the Community and select yours...Analiz Makalesi • Aug 04
Insulet (NASDAQ:PODD) Has A Rock Solid Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Jul 22
Does Insulet (NASDAQ:PODD) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analiz Makalesi • Jun 25
Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analiz Makalesi • May 28
What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?
Insulet Corporation ( NASDAQ:PODD ) received a lot of attention from a substantial price increase on the NASDAQGS over...Seeking Alpha • Mar 18
Insulet Leans Bullish (Technical Analysis)
Summary PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with the PPO line above zero indicating positive long-term momentum. Volume analysis shows neutral to slightly bullish accumulation by institutional investors, with recent high volume supporting bullish price action. Fundamentally, PODD boasts strong earnings and revenue growth, high gross margins, and favorable Wall Street ratings, offering a 3.2 to 1 reward to risk ratio. Read the full article on Seeking AlphaSeeking Alpha • Nov 20
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Summary Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectations and potential competition from giants like Medtronic and Abbott pose significant risks to Insulet's future performance. The company's financials are robust, with rising revenues, margins, and a strong cash position, but the stock's high valuation demands continued exceptional growth. Given the uncertainties and high expectations, I recommend a "Hold" rating, with a cautious approach to see if Insulet can dominate the Type 2 diabetes market. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$303m |
| Dec 31 2025 | US$19m | US$730k | US$247m |
Tazminat ve Piyasa: Ashley 'ın toplam tazminatı ($USD 19.10M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 14.80M ).
Tazminat ve Kazançlar: Ashley şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.
CEO
Ashley McEvoy (54 yo)
1.1yrs
Görev süresi
US$19,101,995
Tazminat
Ms. Ashley A. McEvoy serves as Chief Executive Officer, President and Director of Insulet Corporation since April 28, 2025. She serves as Independent Director of The Procter & Gamble Company since December...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | US$19.10m | 0.0089% $ 963.1k | |
| Executive VP & CFO | less than a year | US$5.47m | 0.0016% $ 172.5k | |
| Executive VP & COO | less than a year | US$4.46m | 0.023% $ 2.5m | |
| Senior VP & General Counsel | 7.2yrs | US$3.13m | 0.033% $ 3.6m | |
| Senior Vice President of Global Operations | no data | US$2.54m | 0.010% $ 1.1m | |
| Senior VP & CTO | 1.2yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations | 1.3yrs | Veri yok | Veri yok | |
| Senior VP and Chief Quality | less than a year | Veri yok | Veri yok | |
| Senior Director of Corporate Communications | no data | Veri yok | Veri yok | |
| Senior Vice President of Sales & Customer Care | 11.3yrs | Veri yok | Veri yok | |
| Senior VP of Strategy & Corporate Development | 2.1yrs | Veri yok | Veri yok | |
| Senior VP & Chief Human Resources Officer | less than a year | Veri yok | Veri yok |
1.1yrs
Ortalama Görev Süresi
52.5yo
Ortalama Yaş
Deneyimli Yönetim: PODD 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 1.1yrs | US$19.10m | 0.0089% $ 963.1k | |
| Independent Chair | 4.3yrs | US$345.72k | 0.0064% $ 698.5k | |
| Chairman of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Educator Advisory Board | no data | Veri yok | Veri yok | |
| Member of Educator Advisory Board | no data | Veri yok | Veri yok | |
| Member of Educator Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Educator Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 2.3yrs | US$344.74k | 0.0044% $ 481.6k | |
| Independent Director | 10.8yrs | US$330.28k | 0.039% $ 4.2m |
3.3yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: PODD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 06:20 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Insulet Corporation 50 Bu analistlerden 24, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |
| Matthew Miksic | Barclays |